Breakthrough Immunotherapy 2026

Precision
Immunity for Targeted Healing.

Swift Elixir is redefining oncology through next-generation immune system engineering. Faster detection, smarter targeting, and rapid restoration.

42+

Clinical Trials

94%

Success Rate

99.9%

Target Accuracy

120+

Patents Filed

Core Innovation

Advanced Biotech Ecosystem

Rapid Response

Bio-engineered T-cells that activate within seconds of detecting malignant cellular signatures, stopping spread immediately.

Immune Shield

Strengthening healthy cellular structures while isolating target infections to prevent systemic degradation.

Nano-Precision

Molecular-scale therapy delivery ensuring absolute specificity and zero collateral damage to vital organs.

Clinical Data

Active Development Pipeline

Tracking the progress of our proprietary immunotherapies and targeted molecular compounds from discovery through late-stage clinical trials.

SE-104
CD19 / T-Cell Engager
Relapsed B-cell Lymphoma
Pre Ph 1 Ph 2 Ph 3
SE-201
PD-1 / Checkpoint Inhibitor
Advanced Melanoma
Pre Ph 1 Ph 2 Ph 3
SE-315
KRAS G12C Inhibitor
Non-Small Cell Lung Cancer
Pre Ph 1 Ph 2 Ph 3

Leadership

Scientific Advisory Board

Guided by decades of pioneering research in molecular biology and immuno-oncology.

Dr. Aris Thorne, MD, PhD

Chief Scientific Officer

Former head of Immunology at global research institutes, pioneering CAR-T cell innovations.

Dr. Elena Rostova

Head of Precision Oncology

Leading expert in targeted genetic editing and CRISPR-based therapeutic applications.

Marcus Vance, PharmD

VP Clinical Development

Oversees global clinical trial execution ensuring rapid regulatory approvals and safety.

Pioneering the Future of Regenerative Medicine.

Join the global clinical network and be part of the most significant advancement in oncology this decade.